A Randomized, Double-blinded, Multiple Ascending Dose Study in Patients With Early-stage Parkinson's Disease to Evaluate the Pharmacokinetics and Safety of LY03003 Following Intramuscular Injections

Trial Profile

A Randomized, Double-blinded, Multiple Ascending Dose Study in Patients With Early-stage Parkinson's Disease to Evaluate the Pharmacokinetics and Safety of LY03003 Following Intramuscular Injections

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Mar 2016

At a glance

  • Drugs Rotigotine (Primary)
  • Indications Parkinson's disease
  • Focus Pharmacokinetics
  • Acronyms 03003MAD
  • Sponsors Luye Pharma Group
  • Most Recent Events

    • 11 Mar 2016 Data from this and another phase I trial (CTP 700269112) will support a New Drug Application (NDA) via a 505(b)(2) pathway to the US FDA for LY03003.
    • 31 Aug 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Jun 2015 Planned End Date changed from 1 May 2015 to 1 Jul 2015 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top